Global Kidney Cancer Drugs Market
Market Size in USD Million
CAGR :
% 
USD
6.30 Million
USD
9.90 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 6.30 Million |
 Market Size (Forecast Year) |
USD 9.90 Million |
 CAGR |
% |
| Major Markets Players |
|
Global Kidney Cancer Drugs Market, By Type (Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Transitional Cell Carcinoma, Wilms Tumor (Nephroblastoma), Renal Sarcoma, Angiomyolipoma, Oncocytoma, Others), Drug Class (Monoclonal Antibodies, mTOR Inhibitors, Immune Checkpoint Inhibitor, Combined Therapies, Interleukin-2, Alpha-Interferon, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Kidney Cancer Drugs Market Analysis and Size
The kidney cancer drugs market is anticipated to witness major growth during the forecast period. Increasing incidence of chronic kidney diseases globally and the rising markets are the factors that are responsible for increasing this market. Kidney cancer accounts for around 2.0% of total adult malignancies worldwide and makes up for 3.8% of all new cancer cases in U.S. The growth of kidney cancer drugs market is improved by the increasing cases of kidney diseases and the increase in R&D activities conducted by several pharmaceutical companies.
Data Bridge Market Research analyses a growth rate in the kidney cancer drugs market in the forecast period 2023-2030. The expected CAGR of kidney cancer drugs market is tend to be around 5.90 % in the mentioned forecast period. The market is valued at USD 6.30 million in 2022, and it will grow upto USD 9.9 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Kidney Cancer Drugs Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Transitional Cell Carcinoma, Wilms Tumor (Nephroblastoma), Renal Sarcoma, Angiomyolipoma, Oncocytoma, Others), Drug Class (Monoclonal Antibodies, mTOR Inhibitors, Immune Checkpoint Inhibitor, Combined Therapies, Interleukin-2, Alpha-Interferon, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.) |
|
Market Opportunities |
|
Market Definition
Kidney cancer drugs are a great boon to patients in controlling numerous problems which cause conditions and complications during kidney diseases. It helps treat several symptoms of kidney failure such as loss of appetite, anemia, and feeling out of breath. However, kidney transplantation is considered to be the most standard treatment for advanced kidney disease. At the advanced stage of kidney cancer, where removal of the cancerous cells is essential, surgical removal of kidney is done to get cure from the disease.
Kidney Cancer Drugs Market Dynamics
Drivers
- Increased Incidence of Kidney Diseases
The increasing incidence of chronic kidney disease globally is majorly responsible for driving the growth of the kidney cancer drugs market. As per the National Kidney Foundation, around 10% of the population is majorly affected by chronic kidney disease (CKD). Renal cell carcinoma accounts for more than 90.0% of all kidney cancers while renal pelvis cancer makes up for <10.0% of microscopically confirmed kidney carcinomas. Clear cell renal cell carcinoma is the most widespread subtype of renal cell carcinoma, affecting around 70.0% of patients with RCC. This demands the increase in kidney cancer drugs.
- Increasing Demand for Immunotherapies
Increasing preference for novel immunotherapies and immune-oncologic agents will push the wide use of targeted therapies to particular patient subpopulations. Programmed death-1 (PD-1) inhibitors are meant to displace TKIs and mTOR inhibitors and work as the primary care in first-and second-line RCC settings. Combination regimens, especially those including PD-1 inhibitors, will be launched in the first-line setting to target major unmet needs, improve progression-free survival, overcome tumor resistance, and maintain the quality of life. Thus, this treatment type is enhancing the market growth.
Opportunities
- Higher Trend of Drug Approvals
The rising approval from the FDA and other authorities for the kidney cancer drugs creates several opportunities for the market growth. For instance, Marck Sharp and Dohme Corp. got approval from Food and Drug Administration (FDA) for KEYTRUDA for the treatment of patients suffering from kidney cancer cell carcinoma. Therefore, all these factors enhance the market expansion.
- Increasing Healthcare Expenditure
The rising expenditure that several organizations are funding lead to the growth of the market. For instance, China offers strong opportunities for market expansion because of the ongoing Healthy China 2020 healthcare reform and the removal of price caps on all medicine categories. The Chinese government has started a supportive 12th Five-Year Plan measures which targets biotechnology as a vital development sector. Moreover, the presence of a large target base with strong unmet clinical needs is expected to boost the market growth.
Restraints/Challenges
- Side Effects of Kidney cancer Drugs
The major side effects related with these kidney cancer drugs could limit the growth of the kidney cancer drugs market during the forecast period. Effects such as loss of appetite, fever, rashes, can impede the market growth.
- High Cost of Treatment
The huge expenditure associated with these agents hamper the market growth. The generic renal cancer treatments are quite expensive and thus is not affordable to many of the patients. Thus, it hampers the market growth.
This global kidney cancer drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global kidney cancer drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Kidney Cancer Drugs Market
The COVID-19 pandemic negatively impacted the market due to the reduction in R&D activities for kidney cancer drugs. For instance, per the data published by the National Center for Biotechnology Information in May 2020, the physicians were focused on developing the SARS-CoV-2 vaccine to avoid the rapid spread of the virus globally. Capacity for surgery has also been minimized as theater space and ventilators have been requisitioned to provide extra critical care capacity for COVID-19 patients. Thus, overall, COVID-19 had a major impact on the kidney cancer drugs market.
Recent Developments
- In 2022, Clinical Hospital of the Faculty of Medicine of Ribeirão Preto partnered with Bristol Myers Squibb and São Paulo Research Foundation for the launch of Nivolumab- new drug on renal cancer. Nivolumab is in the Phase 2 clinical trial whose study was initiated in January 18 2022.
Global Kidney Cancer Drugs Market Scope
The kidney cancer drugs market is segmented on the basis of type, drug type, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Renal Cell Carcinoma (RCC)
- Papillary Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Unclassified Renal Cell Carcinoma
- Transitional Cell Carcinoma
- Wilms Tumor (Nephroblastoma)
- Renal Sarcoma
- Angiomyolipoma
- Oncocytoma
- Others
Drug Class
- Monoclonal Antibodies
- Trastuzumab
- Pertuzumab
- mTOR Inhibitors
- Sirolimus
- Everolimus
- Temsirolimus
- Immune Checkpoint Inhibitor
- Atezolizumab
- Avelumab
- Durvalumab
- Combined Therapies
- Interleukin-2
- Alpha-Interferon
- Others
Drug Type
- Branded
- Generic
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Kidney Cancer Drugs Market Regional Analysis/Insights
The kidney cancer drugs market is analyzed and market size insights and trends are provided by type, drug type, drug class, distribution channel and end-user as referenced above.
The major countries covered in the kidney cancer drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a highest growth for kidney cancer drugs market throughout the forecasted period due to high smoking, hypertension and diabetic population, and wide presence of major key manufactures of the product.
North America dominates the market due to the wide presence of increased healthcare expenditure and favourable reimbursement policies for the treatment. Furthermore, Europe accounts the second largest market share because of the increased genetic disorders and presence of refined medical facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Kidney Cancer Drugs Market Share Analysis
The kidney cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to kidney cancer drugs market.
Key players operating in the kidney cancer drugs market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL KIDNEY CANCER DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL KIDNEY CANCER DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL KIDNEY CANCER DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 EPIDEMOLOGY OF KIDNEY CANCER
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 PIPELINE ANALYSIS
10 TREATMENT TEAM
11 GLOBAL KIDNEY CANCER DRUGS MARKET, BY DRUGS CLASS
11.1 OVERVIEW
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB SEGMENTS)
11.2 MONOCLONAL ANTIBODIES
11.2.1 CETUXIMAB
11.2.2 PANITUMUMAB
11.2.3 ZALUTUMUMAB
11.2.4 NIMOTUZUMAB
11.3 TYROSINE KINASE INHIBITORS
11.3.1 SUNITINIB
11.3.2 SORAFENIB
11.3.3 PAZOPANIB
11.3.4 CABOZANTINIB
11.3.5 LENVATINIB
11.3.6 AXITINIB
11.3.7 TIVOZAQNIB
11.3.8 OTHERS
11.4 MTOR INHIBITORS
11.4.1 TEMSIROLIMUS
11.4.2 EVEROLIMUS
11.5 IMMUNE CHECKPOINT INHIBITOR
11.5.1 NIVOLUMAB
11.5.2 AVELUMAB
11.5.3 PEMBROLIZUMAB
11.6 COMBINED THERAPIES
11.6.1 AXITINIB WITH PEMBROLIZUMAB
11.6.2 AXITINIB WITH AVELUMAB
11.6.3 CABOZANTINIB WITH NIVOLUMAB
11.6.4 LENVATINIB WITH PEMBROLIZUMAB
11.7 CTLA-4 INHIBITORS
11.8 CYTOKINES
11.8.1 INTERLEUKIN-2
11.8.2 ALPHA-INTERFERON
11.9 OTHERS
12 GLOBAL KIDNEY CANCER DRUGS MARKET, BY THERAPY
12.1 OVERVIEW
12.2 CHEMOTHERAPY
12.2.1 CISPLATIN
12.2.2 5-FLUOROURACIL (5-FU)
12.2.3 GEMCITABINE
12.3 TARGATEDTHERAPY
12.3.1 TYROSINE KINASE INHIBITORS
12.3.2 ALPHA-INTERFERON
12.3.3 MTOR INHIBITORS
12.3.4 OTHERS
12.4 IMMUNOTHERAPY
12.4.1 IMMUNE CHECKPOINT INHIBITOR
12.4.2 CYTOKINES
12.4.3 OTHERS
13 GLOBAL KIDNEY CANCER DRUGS MARKET, BY TYPE
13.1 OVERVIEW
13.2 RENAL CELL CARCINOMA (RCC)
13.3 PAPILLARY RENAL CELL CARCINOMA
13.4 CHROMOPHOBE RENAL CELL CARCINOMA
13.5 UNCLASSIFIED RENAL CELL CARCINOMA
13.6 TRANSITIONAL CELL CARCINOMA
13.7 WILMS TUMOR (NEPHROBLASTOMA)
13.8 RENAL SARCOMA
13.9 ANGIOMYOLIPOMA
13.1 ONCOCYTOMA
13.11 OTHERS
14 GLOBAL KIDNEY CANCER DRUGS MARKET, BY STAGES
14.1 OVERVIEW
14.2 STAGE I
14.3 STAGE II
14.4 STAGE III
14.5 STAGE IV
15 GLOBAL KIDNEY CANCER DRUGS MARKET, BY DRUG TYPE
15.1 OVERVIEW
15.2 BRANDED
15.2.1 KEYTRUDA
15.2.2 AFINITOR
15.2.3 TORISEL
15.2.4 INLYTA
15.2.5 CABOMETYX
15.2.6 AVASTIN
15.2.7 VOTRIENT
15.2.8 LENVIMA
15.2.9 NEXAVAR
15.2.10 SUTENT
15.2.11 FOTIVDA
15.2.12 MVASI
15.2.13 ZIRABEV
15.2.14 OPDIVO
15.3 GENERIC
16 GLOBAL KIDNEY CANCER DRUGS MARKET, BY GENDER
16.1 OVERVIEW
16.2 MALE
16.2.1 BELOW 30 YRS
16.2.2 30-45 YRS
16.2.3 ABOVE 45 YRS
16.3 FEMALE
16.3.1 BELOW 30 YRS
16.3.2 30-45 YRS
16.3.3 ABOVE 45 YRS
17 GLOBAL KIDNEY CANCER DRUGS MARKET, BY DOSAGE FORM
17.1 OVERVIEW
17.2 ORAL
17.2.1 TABLETS
17.2.2 CAPSULES
17.3 PARENTRAL
17.4 OTHERS
18 GLOBAL KIDNEY CANCER DRUGS MARKET, BY END USER
18.1 OVERVIEW
18.2 HOSPITALS
18.3 SPECIALITY CLINICS
18.4 CLINICS
18.5 ACADEMIC AND RESEARCH INSTITUTES
18.6 OTHERS
19 GLOBAL KIDNEY CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
19.1 OVERVIEW
19.2 DIRECT TENDER
19.3 RETAIL SALES
19.3.1 HOSPITAL PHARMACY
19.3.2 RETAIL PHARMACY
19.3.3 ONLINE PHARMACY
20 GLOBAL KIDNEY CANCER DRUGS MARKET, BY REGION
20.1 GLOBAL KIDNEY CANCER DRUGS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
20.2 NORTH AMERICA
20.2.1 U.S.
20.2.2 CANADA
20.2.3 MEXICO
20.3 EUROPE
20.3.1 GERMANY
20.3.2 U.K.
20.3.3 ITALY
20.3.4 FRANCE
20.3.5 SPAIN
20.3.6 RUSSIA
20.3.7 SWITZERLAND
20.3.8 TURKEY
20.3.9 BELGIUM
20.3.10 NETHERLANDS
20.3.11 DENMARK
20.3.12 SWEDEN
20.3.13 POLAND
20.3.14 NORWAY
20.3.15 FINLAND
20.3.16 REST OF EUROPE
20.4 ASIA-PACIFIC
20.4.1 JAPAN
20.4.2 CHINA
20.4.3 SOUTH KOREA
20.4.4 INDIA
20.4.5 SINGAPORE
20.4.6 THAILAND
20.4.7 INDONESIA
20.4.8 MALAYSIA
20.4.9 PHILIPPINES
20.4.10 AUSTRALIA
20.4.11 NEW ZEALAND
20.4.12 VIETNAM
20.4.13 TAIWAN
20.4.14 REST OF ASIA-PACIFIC
20.5 SOUTH AMERICA
20.5.1 BRAZIL
20.5.2 ARGENTINA
20.5.3 REST OF SOUTH AMERICA
20.6 MIDDLE EAST AND AFRICA
20.6.1 SOUTH AFRICA
20.6.2 EGYPT
20.6.3 BAHRAIN
20.6.4 UNITED ARAB EMIRATES
20.6.5 KUWAIT
20.6.6 OMAN
20.6.7 QATAR
20.6.8 SAUDI ARABIA
20.6.9 REST OF MIDDLE EAST AND AFRICA
20.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
21 GLOBAL KIDNEY CANCER DRUGS MARKET, COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: GLOBAL
21.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
21.3 COMPANY SHARE ANALYSIS: EUROPE
21.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21.5 MERGERS & ACQUISITIONS
21.6 NEW PRODUCT DEVELOPMENT & APPROVALS
21.7 EXPANSIONS
21.8 REGULATORY CHANGES
21.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 GLOBAL KIDNEY CANCER DRUGS MARKET, COMPANY PROFILE
22.1 NOVARTIS PHARMACEUTICALS CORPORATION
22.1.1 COMPANY OVERVIEW
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 MERCK & CO., INC.,
22.2.1 COMPANY OVERVIEW
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPEMENTS
22.3 CLINIGEN LIMITED
22.3.1 COMPANY OVERVIEW
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPEMENTS
22.4 PFIZER INC.
22.4.1 COMPANY OVERVIEW
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPEMENTS
22.5 ASTRAZENECA
22.5.1 COMPANY OVERVIEW
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPEMENTS
22.6 BRISTOL-MYERS SQUIBB COMPANY
22.6.1 COMPANY OVERVIEW
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPEMENTS
22.7 EXELIXIS, INC.
22.7.1 COMPANY OVERVIEW
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPEMENTS
22.8 GENENTECH USA, INC.
22.8.1 COMPANY OVERVIEW
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPEMENTS
22.9 EISAI INC.
22.9.1 COMPANY OVERVIEW
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPEMENTS
22.1 BAYER AG
22.10.1 COMPANY OVERVIEW
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPEMENTS
22.11 AVEO PHARMACEUTICALS, INC.
22.11.1 COMPANY OVERVIEW
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPEMENTS
22.12 AMGEN INC.
22.12.1 COMPANY OVERVIEW
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPEMENTS
22.13 AMNEAL PHARMACEUTICALS LLC.
22.13.1 COMPANY OVERVIEW
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPEMENTS
22.14 WEBMD LLC.
22.14.1 COMPANY OVERVIEW
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPEMENTS
22.15 QUESTEX LLC
22.15.1 COMPANY OVERVIEW
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPEMENTS
22.16 ALLEVIARE LIFE SCIENCES PVT. LTD.
22.16.1 COMPANY OVERVIEW
22.16.2 REVENUE ANALYSIS
22.16.3 GEOGRAPHIC PRESENCE
22.16.4 PRODUCT PORTFOLIO
22.16.5 RECENT DEVELOPEMENTS
22.17 ENDO INTERNATIONAL PLC
22.17.1 COMPANY OVERVIEW
22.17.2 REVENUE ANALYSIS
22.17.3 GEOGRAPHIC PRESENCE
22.17.4 PRODUCT PORTFOLIO
22.17.5 RECENT DEVELOPEMENTS
22.18 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
22.18.1 COMPANY OVERVIEW
22.18.2 REVENUE ANALYSIS
22.18.3 GEOGRAPHIC PRESENCE
22.18.4 PRODUCT PORTFOLIO
22.18.5 RECENT DEVELOPEMENTS
22.19 ABBOTT
22.19.1 COMPANY OVERVIEW
22.19.2 REVENUE ANALYSIS
22.19.3 GEOGRAPHIC PRESENCE
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPEMENTS
22.2 F. HOFFMANN-LA ROCHE LTD
22.20.1 COMPANY OVERVIEW
22.20.2 REVENUE ANALYSIS
22.20.3 GEOGRAPHIC PRESENCE
22.20.4 PRODUCT PORTFOLIO
22.20.5 RECENT DEVELOPEMENTS
22.21 FRESENIUS KABI USA
22.21.1 COMPANY OVERVIEW
22.21.2 REVENUE ANALYSIS
22.21.3 GEOGRAPHIC PRESENCE
22.21.4 PRODUCT PORTFOLIO
22.21.5 RECENT DEVELOPEMENTS
22.22 SANOFI
22.22.1 COMPANY OVERVIEW
22.22.2 REVENUE ANALYSIS
22.22.3 GEOGRAPHIC PRESENCE
22.22.4 PRODUCT PORTFOLIO
22.22.5 RECENT DEVELOPEMENTS
22.23 BIOCON
22.23.1 COMPANY OVERVIEW
22.23.2 REVENUE ANALYSIS
22.23.3 GEOGRAPHIC PRESENCE
22.23.4 PRODUCT PORTFOLIO
22.23.5 RECENT DEVELOPEMENTS
22.24 VIATRIS
22.24.1 COMPANY OVERVIEW
22.24.2 REVENUE ANALYSIS
22.24.3 GEOGRAPHIC PRESENCE
22.24.4 PRODUCT PORTFOLIO
22.24.5 RECENT DEVELOPEMENTS
22.25 TEVA PHARMACEUTICAL INDUSTRIES LTD.
22.25.1 COMPANY OVERVIEW
22.25.2 REVENUE ANALYSIS
22.25.3 GEOGRAPHIC PRESENCE
22.25.4 PRODUCT PORTFOLIO
22.25.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
